Blood test could unlock why lung cancer drugs stop working
NCT ID NCT03833934
Summary
This study aimed to understand why some lung cancers become resistant to targeted drugs. Researchers used a simple blood test, instead of a tissue biopsy, to look for genetic changes in 62 patients with ALK-positive lung cancer whose cancer had started growing again during treatment. The goal was to gather knowledge about the different types of resistance that develop, which could help guide future treatment choices.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.